These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23433442)

  • 21. Safety, tolerability and pharmacokinetics of AFN-1252 administered as immediate release tablets in healthy subjects.
    Hafkin B; Kaplan N; Hunt TL
    Future Microbiol; 2015; 10(11):1805-13. PubMed ID: 26357940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457.
    Hilliard JJ; Fernandez J; Melton J; Macielag MJ; Goldschmidt R; Bush K; Abbanat D
    Antimicrob Agents Chemother; 2009 May; 53(5):2028-33. PubMed ID: 19273686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.
    MacGowan AP; Noel AR; Tomaselli S; Elliott HC; Bowker KE
    Antimicrob Agents Chemother; 2011 Feb; 55(2):867-73. PubMed ID: 21078943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pharmacodynamics of fosfomycin against Staphylococcus aureus studied in an in vitro model of infection.
    Noel A; Attwood M; Bowker K; MacGowan A
    Int J Antimicrob Agents; 2020 Jul; 56(1):105985. PubMed ID: 32330585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cellular pharmacokinetics and intracellular activity of the bacterial fatty acid synthesis inhibitor, afabicin desphosphono against different resistance phenotypes of Staphylococcus aureus in models of cultured phagocytic cells.
    Peyrusson F; Van Wessem A; Dieppois G; Van Bambeke F; Tulkens PM
    Int J Antimicrob Agents; 2020 Feb; 55(2):105848. PubMed ID: 31770623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In Vitro Pharmacodynamics of Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus: Considering the Variability in Observed Tissue Exposure.
    Hamada Y; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2016 Feb; 60(2):955-61. PubMed ID: 26621619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The pharmacodynamics of minocycline alone and in combination with rifampicin against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.
    Noel AR; Attwood M; Bowker KE; MacGowan AP
    J Antimicrob Chemother; 2021 Jun; 76(7):1840-1844. PubMed ID: 33975336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model.
    Lepak AJ; Marchillo K; Pichereau S; Craig WA; Andes DR
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5916-22. PubMed ID: 22964254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates.
    Keel RA; Crandon JL; Nicolau DP
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4028-32. PubMed ID: 21670184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
    Mendes RE; Moet GJ; Janechek MJ; Jones RN
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2704-6. PubMed ID: 20385851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Leonard SN
    PLoS One; 2012; 7(7):e42103. PubMed ID: 22848719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activity of gallium maltolate against Staphylococci in logarithmic, stationary, and biofilm growth phases: comparison of conventional and calorimetric susceptibility testing methods.
    Baldoni D; Steinhuber A; Zimmerli W; Trampuz A
    Antimicrob Agents Chemother; 2010 Jan; 54(1):157-63. PubMed ID: 19805560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Dilworth TJ; Leonard SN; Vilay AM; Mercier RC
    Clin Ther; 2014 Oct; 36(10):1334-44. PubMed ID: 25066667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacodynamic Profile of GSK2140944 against Methicillin-Resistant Staphylococcus aureus in a Murine Lung Infection Model.
    So W; Crandon JL; Nicolau DP
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4956-61. PubMed ID: 26055376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection.
    Hoover J; Lewandowski T; Straub RJ; Novick SJ; DeMarsh P; Aubart K; Rittenhouse S; Zalacain M
    Antimicrob Agents Chemother; 2016 Jan; 60(1):180-9. PubMed ID: 26482300
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibiotic Resistance in the Treatment of Staphylococcus aureus Keratitis: a 20-Year Review.
    Chang VS; Dhaliwal DK; Raju L; Kowalski RP
    Cornea; 2015 Jun; 34(6):698-703. PubMed ID: 25811722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure.
    Lenhard JR; Brown T; Rybak MJ; Meaney CJ; Norgard NB; Bulman ZP; Brazeau DA; Gill SR; Tsuji BT
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1584-91. PubMed ID: 26711763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimicrobial susceptibility patterns and characterization of clinical isolates of Staphylococcus aureus in immunocompromised cancer patients undergoing chemotherapy in Pakistan.
    Younus A; Faiz M; Saleem M; Saghir S
    J Chemother; 2009 Feb; 21(1):31-5. PubMed ID: 19297269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.
    Singh R; Almutairi M; Alm RA; Lahiri SD; San Martin M; Chen A; Ambler JE
    J Antimicrob Chemother; 2017 Oct; 72(10):2796-2803. PubMed ID: 29091195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms.
    Bauer J; Siala W; Tulkens PM; Van Bambeke F
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2726-37. PubMed ID: 23571532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.